Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | SDCBP | O00560 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11538170 | 0.94 | HSD17B10 (0.59) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL11538173 | 0.90 | HSD17B10 (0.54) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL13438254 | 0.82 | TSHR (0.58) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL10455020 | 0.82 | KDM4E (0.47) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL11574943 | 0.82 | HPGD (0.57) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL5110593 | 0.82 | GAA (0.53) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL10455022 | 0.82 | KDM4E (0.47) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL1931354 | 0.81 | KDM4E (0.51) | HSD17B10LMNANPSR1SMN1; SMN2L3MBTL1 | |
| SCHEMBL7048451 | 0.80 | MEN1 (0.51) | CYP2C9CYP2C19HSD17B10TSHRHPGD | |
| SCHEMBL875038 | 0.80 | KDM4E (0.46) | CYP2C9CYP2C19HSD17B10TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| CN-110229333-B | Synthetic method of polyimide | 湘潭大学 | 2022-02-15 | — | — | CN | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-5583142-A | TROPANYL-PHENYL OR NAPHTHYL-CARBOXYLATE OR CARBAMYLATE COMPOUNDS; LEARNING ENHANCEMENT | FIDIA S.P.A. (IT) | 1996-12-10 | — | — | US | disclosed |
| EP-0650486-A1 | NEW ANALGESIC AND NOOTROPIC DRUGS | FIDIA S.p.A. (IT) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994001435-A1 | NEW ANALGESIC AND NOOTROPIC DRUGS | FIDIA S.P.A. (IT) | 1994-01-20 | — | — | WO | disclosed |
| US-4528286-A | Method of using certain aryl-mercapto-lower-alkanamides as antiseborrheic agents | HENKEL KOMMANDITGESELLSCHAFT (KGAA) (DE) | 1985-07-09 | — | — | US | disclosed |
| US-4268516-A | [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents | PFIZER INC. (US) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | CYP2C9 4866/4885CYP2C19 4874/4885HSD17B10 2401/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | CYP2C9 4031/4885CYP2C19 4208/4885HSD17B10 1321/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | CYP2C9 4866/4885CYP2C19 4874/4885HSD17B10 2401/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP2C9 4788/4885CYP2C19 4866/4885HSD17B10 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.